# Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Source: https://onco.cc/trials/nct05663866/  
OnCo record `nct05663866` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Dexamethasone, Methotrexate, Amivantamab and Lazertinib in non-small-cell lung cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.

## Summary

Premedication to Reduce Amivantamab Associated Infusion Related Reactions is a phase 2 interventional study registered as NCT05663866 by Janssen Research & Development, LLC, with 68 participants enrolled, started 2023-05-18 and due to reach its primary completion in 2024-03-29. Interventions recorded: Dexamethasone, Montelukast, Methotrexate, Amivantamab and Lazertinib. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05663866
- Phase: 2
- Setting: Subcutaneous Methotrexate, Oral Dexamethasone or Oral Montelukast for the Prevention of Infusion Related Reaction Associated With Amivantamab, an EGFR-MET Bispecific Antibody, Among Post-osimertinib Treated EGFRm NSCLC; SKIPPirr, a Phase 2 Study
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 68

## Sources

- ClinicalTrials.gov NCT05663866: https://clinicaltrials.gov/study/NCT05663866

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Amivantamab](https://onco.cc/drugs/amivantamab/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Lazertinib](https://onco.cc/drugs/lazertinib/), [Methotrexate](https://onco.cc/drugs/methotrexate/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct05663866.json